For citations:
Chubenko V.A., Baklanova O.V., Kalpinskiy A.S., Safina S.Z., Lebedinets A.A., Petkau V.V., Parsadanova E.L., Anzhiganova Yu.V., Novikova O.Yu., Bragina V.S., Tkacheva E.V., Shkurat A.O., Gluzman M.I., Zukov R.A., Tsimafeyeu I.V. Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial. Cancer Urology. 2025;21(2):25-32. (In Russ.) https://doi.org/10.17650/1726-9776-2025-21-2-25-32
Email this article 